GSK PLC (GS71.DE) Fundamental Analysis & Valuation

FRA:GS71 • GB00BN7SWP63

Current stock price

23.28 EUR
-0.17 (-0.72%)
Last:

This GS71.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. GS71.DE Profitability Analysis

1.1 Basic Checks

  • In the past year GS71 was profitable.
  • GS71 had a positive operating cash flow in the past year.
  • GS71 had positive earnings in each of the past 5 years.
  • Each year in the past 5 years GS71 had a positive operating cash flow.
GS71.DE Yearly Net Income VS EBIT VS OCF VS FCFGS71.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 9.35%, GS71 is in the better half of the industry, outperforming 67.31% of the companies in the same industry.
  • GS71 has a Return On Equity of 34.90%. This is amongst the best in the industry. GS71 outperforms 82.69% of its industry peers.
  • The Return On Invested Capital of GS71 (19.19%) is better than 73.08% of its industry peers.
Industry RankSector Rank
ROA 9.35%
ROE 34.9%
ROIC 19.19%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GS71.DE Yearly ROA, ROE, ROICGS71.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K -2K

1.3 Margins

  • With a decent Profit Margin value of 17.50%, GS71 is doing good in the industry, outperforming 67.31% of the companies in the same industry.
  • GS71's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 27.47%, GS71 is in the better half of the industry, outperforming 71.15% of the companies in the same industry.
  • GS71's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 72.67%, GS71 is in line with its industry, outperforming 59.62% of the companies in the same industry.
  • GS71's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 27.47%
PM (TTM) 17.5%
GM 72.67%
OM growth 3Y-1.36%
OM growth 5Y2.22%
PM growth 3Y-29.99%
PM growth 5Y-5.81%
GM growth 3Y0.72%
GM growth 5Y0.77%
GS71.DE Yearly Profit, Operating, Gross MarginsGS71.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. GS71.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), GS71 is creating value.
  • There is no outstanding debt for GS71. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GS71.DE Yearly Shares OutstandingGS71.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B
GS71.DE Yearly Total Debt VS Total AssetsGS71.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B

2.2 Solvency

  • Based on the Altman-Z score of 1.75, we must say that GS71 is in the distress zone and has some risk of bankruptcy.
  • GS71 has a worse Altman-Z score (1.75) than 63.46% of its industry peers.
  • The Debt to FCF ratio of GS71 is 3.73, which is a good value as it means it would take GS71, 3.73 years of fcf income to pay off all of its debts.
  • With a decent Debt to FCF ratio value of 3.73, GS71 is doing good in the industry, outperforming 63.46% of the companies in the same industry.
  • GS71 has a Debt/Equity ratio of 0.90. This is a neutral value indicating GS71 is somewhat dependend on debt financing.
  • GS71's Debt to Equity ratio of 0.90 is on the low side compared to the rest of the industry. GS71 is outperformed by 67.31% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF 3.73
Altman-Z 1.75
ROIC/WACC1.98
WACC9.71%
GS71.DE Yearly LT Debt VS Equity VS FCFGS71.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B 20B

2.3 Liquidity

  • GS71 has a Current Ratio of 0.82. This is a bad value and indicates that GS71 is not financially healthy enough and could expect problems in meeting its short term obligations.
  • GS71 has a Current ratio of 0.82. This is amonst the worse of the industry: GS71 underperforms 84.62% of its industry peers.
  • GS71 has a Quick Ratio of 0.82. This is a bad value and indicates that GS71 is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Quick ratio value of 0.54, GS71 is not doing good in the industry: 88.46% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.82
Quick Ratio 0.54
GS71.DE Yearly Current Assets VS Current LiabilitesGS71.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. GS71.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 7.84% over the past year.
  • The Earnings Per Share has been growing slightly by 3.55% on average over the past years.
  • Looking at the last year, GS71 shows a small growth in Revenue. The Revenue has grown by 4.11% in the last year.
  • GS71 shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.05% yearly.
EPS 1Y (TTM)7.84%
EPS 3Y5.13%
EPS 5Y3.55%
EPS Q2Q%9.91%
Revenue 1Y (TTM)4.11%
Revenue growth 3Y3.66%
Revenue growth 5Y6.05%
Sales Q2Q%6.17%

3.2 Future

  • GS71 is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.01% yearly.
  • The Revenue is expected to grow by 2.87% on average over the next years.
EPS Next Y8.66%
EPS Next 2Y8.39%
EPS Next 3Y6.8%
EPS Next 5Y5.01%
Revenue Next Year4.21%
Revenue Next 2Y4.48%
Revenue Next 3Y3.95%
Revenue Next 5Y2.87%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
GS71.DE Yearly Revenue VS EstimatesGS71.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B
GS71.DE Yearly EPS VS EstimatesGS71.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

8

4. GS71.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 11.70, the valuation of GS71 can be described as very reasonable.
  • GS71's Price/Earnings ratio is rather cheap when compared to the industry. GS71 is cheaper than 80.77% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of GS71 to the average of the S&P500 Index (26.11), we can say GS71 is valued rather cheaply.
  • The Price/Forward Earnings ratio is 10.77, which indicates a very decent valuation of GS71.
  • Based on the Price/Forward Earnings ratio, GS71 is valued cheaply inside the industry as 82.69% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.12, GS71 is valued rather cheaply.
Industry RankSector Rank
PE 11.7
Fwd PE 10.77
GS71.DE Price Earnings VS Forward Price EarningsGS71.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, GS71 is valued cheaper than 98.08% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of GS71 indicates a rather cheap valuation: GS71 is cheaper than 96.15% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 8.49
EV/EBITDA 4.29
GS71.DE Per share dataGS71.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • GS71's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The decent profitability rating of GS71 may justify a higher PE ratio.
PEG (NY)1.35
PEG (5Y)3.29
EPS Next 2Y8.39%
EPS Next 3Y6.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. GS71.DE Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 3.45%, GS71 has a reasonable but not impressive dividend return.
  • Compared to an average industry Dividend Yield of 1.92, GS71 pays a bit more dividend than its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.91, GS71 pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.45%

5.2 History

  • The dividend of GS71 decreases each year by -9.84%.
Dividend Growth(5Y)-9.84%
Div Incr Years2
Div Non Decr Years2
GS71.DE Yearly Dividends per shareGS71.DE Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 2026 0.2 0.4 0.6

5.3 Sustainability

  • 44.86% of the earnings are spent on dividend by GS71. This is a bit on the high side, but may be sustainable.
DP44.86%
EPS Next 2Y8.39%
EPS Next 3Y6.8%
GS71.DE Yearly Income VS Free CF VS DividendGS71.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B
GS71.DE Dividend Payout.GS71.DE Dividend Payout, showing the Payout Ratio.GS71.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

GS71.DE Fundamentals: All Metrics, Ratios and Statistics

GSK PLC

FRA:GS71 (3/17/2026, 7:00:00 PM)

23.28

-0.17 (-0.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-04
Earnings (Next)04-29
Inst Owners41.42%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap46.71B
Revenue(TTM)32.67B
Net Income(TTM)5.72B
Analysts68.75
Price Target23.32 (0.17%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.45%
Yearly Dividend0.69
Dividend Growth(5Y)-9.84%
DP44.86%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.74%
Min EPS beat(2)8.69%
Max EPS beat(2)12.8%
EPS beat(4)4
Avg EPS beat(4)9.75%
Min EPS beat(4)7.67%
Max EPS beat(4)12.8%
EPS beat(8)8
Avg EPS beat(8)11.8%
EPS beat(12)11
Avg EPS beat(12)9.51%
EPS beat(16)15
Avg EPS beat(16)10.21%
Revenue beat(2)0
Avg Revenue beat(2)-0.76%
Min Revenue beat(2)-1.24%
Max Revenue beat(2)-0.28%
Revenue beat(4)0
Avg Revenue beat(4)-0.79%
Min Revenue beat(4)-1.6%
Max Revenue beat(4)-0.04%
Revenue beat(8)3
Avg Revenue beat(8)-0.16%
Revenue beat(12)7
Avg Revenue beat(12)1.25%
Revenue beat(16)9
Avg Revenue beat(16)-0.18%
PT rev (1m)6.61%
PT rev (3m)11.45%
EPS NQ rev (1m)-0.56%
EPS NQ rev (3m)-6.06%
EPS NY rev (1m)-0.14%
EPS NY rev (3m)-0.26%
Revenue NQ rev (1m)-0.28%
Revenue NQ rev (3m)-1.31%
Revenue NY rev (1m)-0.84%
Revenue NY rev (3m)-0.73%
Valuation
Industry RankSector Rank
PE 11.7
Fwd PE 10.77
P/S 1.24
P/FCF 8.49
P/OCF 5.22
P/B 2.47
P/tB N/A
EV/EBITDA 4.29
EPS(TTM)1.99
EY8.55%
EPS(NY)2.16
Fwd EY9.28%
FCF(TTM)2.74
FCFY11.78%
OCF(TTM)4.46
OCFY19.17%
SpS18.84
BVpS9.44
TBVpS-4.26
PEG (NY)1.35
PEG (5Y)3.29
Graham Number20.56
Profitability
Industry RankSector Rank
ROA 9.35%
ROE 34.9%
ROCE 22.59%
ROIC 19.19%
ROICexc 20.98%
ROICexgc 60.71%
OM 27.47%
PM (TTM) 17.5%
GM 72.67%
FCFM 14.56%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-1.36%
OM growth 5Y2.22%
PM growth 3Y-29.99%
PM growth 5Y-5.81%
GM growth 3Y0.72%
GM growth 5Y0.77%
F-Score9
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF 3.73
Debt/EBITDA 1.15
Cap/Depr 79.01%
Cap/Sales 9.14%
Interest Coverage 13.22
Cash Conversion 60.7%
Profit Quality 83.21%
Current Ratio 0.82
Quick Ratio 0.54
Altman-Z 1.75
F-Score9
WACC9.71%
ROIC/WACC1.98
Cap/Depr(3y)99.36%
Cap/Depr(5y)105.31%
Cap/Sales(3y)8.79%
Cap/Sales(5y)9.19%
Profit Quality(3y)103.9%
Profit Quality(5y)92.12%
High Growth Momentum
Growth
EPS 1Y (TTM)7.84%
EPS 3Y5.13%
EPS 5Y3.55%
EPS Q2Q%9.91%
EPS Next Y8.66%
EPS Next 2Y8.39%
EPS Next 3Y6.8%
EPS Next 5Y5.01%
Revenue 1Y (TTM)4.11%
Revenue growth 3Y3.66%
Revenue growth 5Y6.05%
Sales Q2Q%6.17%
Revenue Next Year4.21%
Revenue Next 2Y4.48%
Revenue Next 3Y3.95%
Revenue Next 5Y2.87%
EBIT growth 1Y15.03%
EBIT growth 3Y2.25%
EBIT growth 5Y8.41%
EBIT Next Year28.71%
EBIT Next 3Y11.62%
EBIT Next 5Y8.05%
FCF growth 1Y33.15%
FCF growth 3Y-2.59%
FCF growth 5Y-5.17%
OCF growth 1Y18.11%
OCF growth 3Y1.5%
OCF growth 5Y-1.72%

GSK PLC / GS71.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for GSK PLC?

ChartMill assigns a fundamental rating of 5 / 10 to GS71.DE.


What is the valuation status of GSK PLC (GS71.DE) stock?

ChartMill assigns a valuation rating of 8 / 10 to GSK PLC (GS71.DE). This can be considered as Undervalued.


Can you provide the profitability details for GSK PLC?

GSK PLC (GS71.DE) has a profitability rating of 6 / 10.


Can you provide the PE and PB ratios for GS71 stock?

The Price/Earnings (PE) ratio for GSK PLC (GS71.DE) is 11.7 and the Price/Book (PB) ratio is 2.47.


Can you provide the dividend sustainability for GS71 stock?

The dividend rating of GSK PLC (GS71.DE) is 4 / 10 and the dividend payout ratio is 44.86%.